Compositions and methods of treating muscle dystrophy
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).
1. A small interfering RNA (siRNA) molecule conjugate comprising an anti-transferrin receptor antibody or antigen binding fragment thereof conjugated to a siRNA molecule that hybridizes to a target sequence of DMPK mRNA;
wherein the sense strand of the siRNA comprises the sequence selected from the group consisting of SEQ ID NOs: 3, 5, 7, 9, 11, 13, and 15, and the antisense strand of the siRNA comprises the sequence selected from the group consisting of SEQ ID NOs:
4, 6, 8, 10, 12, 14, and 16; and
wherein the siRNA molecule conjugate mediates RNA interference against DMPK.
2. The siRNA molecule conjugate of claim 1 , wherein the anti-transferrin receptor antibody or antigen binding fragment thereof comprises a humanized antibody or antigen binding fragment thereof, a chimeric antibody or antigen binding fragment thereof, or a multi-specific antibody or antigen binding fragment thereof.
3. The siRNA molecule conjugate of claim 2 , wherein the anti-transferrin receptor antibody or antigen binding fragment thereof comprises an IgG-scFv, nanobody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CH3, triple body, mini-antibody, minibody, TriBi minibody, scFv-CH3 KIH, Fab-scFv-Fc KIH, Fab-scFv, scFv-CH-CL-scFv, F(ab′)2, F(ab′)2-scFv2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, or intrabody.
4. The siRNA molecule conjugate of claim 1 , wherein the anti-transferrin receptor antibody or antigen binding fragment thereof specifically binds to human transferrin receptor (TfR).
5. The siRNA molecule conjugate of claim 1 , wherein the siRNA molecule conjugate comprises a linker connecting the anti-transferrin receptor antibody or antigen binding fragment thereof to the siRNA molecule.
6. A pharmaceutical composition comprising:
a. the siRNA molecule conjugate of claim 1 ; and
b. a pharmaceutically acceptable excipient.
7. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated for parenteral, oral, intranasal, buccal, rectal, intrathecal, or transdermal administration.
8. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated for intravenous administration.
9. The siRNA molecule conjugate of claim 1 , wherein siRNA comprises the sense strand comprising SEQ ID NO:3 and the antisense sequence comprising SEQ ID NO: 4.
10. The siRNA molecule conjugate of claim 1 , wherein the anti-transferrin receptor antibody or antigen binding fragment thereof is conjugated to the siRNA molecule via a linker.
11. The siRNA molecule conjugate of claim 10 , wherein the linker comprises a 4-(N-maleimidomethyl) cyclohexane-1-amidate linker.
12. The siRNA molecule conjugate of claim 10 , wherein the linker is conjugated with the sense strand of the siRNA molecule.
13. The siRNA molecule conjugate of claim 12 , wherein the linker is conjugated with the 5′ end of the sense strand of the siRNA molecule.
14. The siRNA molecule conjugate of claim 10 , wherein the linker comprises a 6-Amino-1-hexanol linker.